Gene expression data from 4T1 irradiated tumors treated with TGFbeta blockade

Accumulating data support the concept that ionizing radiation therapy (RT) has the potential to convert the tumor into an in situ individualized vaccine; however this potential is rarely realized by RT alone. Transforming growth factor xce xb2 (TGF xce xb2) is an immunosuppressive cytokine that is activated by RT and inhibits the antigen-presenting function of dendritic cells and the differentiation of effector CD8+ T cells. Here we tested the hypothesis that TGF xce xb2 hinders the ability of RT to promote anti-tumor immunity. Development of tumor-specific immunity was examined in a pre-clinical model of metastatic breast cancer. Mice bearing established 4T1 mouse mammary carcinoma treated with pan-isoform specific TGF xce xb2 neutralizing antibody 1D11 showed significantly improved control of the irradiated tumor and non-irradiated metastases but no effect in the absence of RT. Notably whole tumor transcriptional analysis demonstrated the selective upregulation of genes associated with immune-mediated rejection only in tumors of mice treated with RT+TGF xce xb2 blockade. Mice treated with RT+TGF xce xb2 blockade exhibited cross-priming of CD8+ T cells producing IFN xce xb3 in response to three tumor-specific antigens in tumor-draining lymph nodes which was not evident for single modality treatment. Analysis of the immune infiltrate in mouse tumors showed a significant increase in CD4+ and CD8+ T cells only in mice treated with the combination of RT+TGF xce xb2 blockade. Depletion of CD4+ or CD8+ T cells abrogated the therapeutic benefit of RT+TGF xce xb2 blockade. These data identify TGF xce xb2 as a master inhibitor of the ability of RT to generate an in situ tumor vaccine which supports testing inhibition of TGF xce xb2 during radiotherapy to promote therapeutically effective anti-tumor immunity. We used genome-wide microarray to depict main biological processes responsibles for the therapeutic benefit of the combination ofTGF-beta blockade and local radiotherapy. To gain a more comprehensice protrait of the effects of RT and TGFbeta blockade on gene expressionin tumors we collected 4T1 tumors 4 days after completion of RT. Three tumors from each group were then subjected to RNA extraction and hybridization on affymetrix array.

Data and Resources

Additional Info

Field Value
Maintainer GeneLab Outreach
Last Updated April 23, 2025, 23:03 (UTC)
Created April 1, 2025, 01:51 (UTC)
accessLevel public
accrualPeriodicity irregular
bureauCode {026:00}
catalog_@context https://project-open-data.cio.gov/v1.1/schema/catalog.jsonld
catalog_@id https://data.nasa.gov/data.json
catalog_conformsTo https://project-open-data.cio.gov/v1.1/schema
catalog_describedBy https://project-open-data.cio.gov/v1.1/schema/catalog.json
harvest_object_id 9da2241c-12e3-43d2-8ad5-52308e809211
harvest_source_id 61638e72-b36c-4866-9d28-551a3062f158
harvest_source_title DNG Legacy Data
identifier nasa_genelab_GLDS-160_vz54-rnde
issued 2021-05-21
landingPage https://data.nasa.gov/dataset/gene-expression-data-from-4t1-irradiated-tumors-treated-with-tgfbeta-blockade
license http://www.usa.gov/publicdomain/label/1.0/
modified 2023-01-26
programCode {026:005}
publisher National Aeronautics and Space Administration
resource-type Dataset
source_datajson_identifier true
source_hash 4652e585a6873c0c9bcfc9efc05c7049971de20767045ef5418e22f55a350543
source_schema_version 1.1
theme {"Earth Science"}